RegeneRx drug candidate, RGN-259, is the subject of two Phase 3 clinical trials in the U.S. for patients with dry eye syndrome and neurotrophic keratopathy (an orphan indication). We expect the results of these trials to be available in 2020.

Another drug candidate, RGN-137, is the subject of a Phase 2 clinical trial in the U.S. in patients with epidermolysis bullosa (an orphan indication). 

The Company’s Chinese partner is currently preparing to sponsor a Phase 2/3 clinical trial with RGN-259 in China in patients with dry eye syndrome.